Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2022-08-16 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - OCC 8 pages 29.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities following the exercise of options or conversion of convertible securities. It details the number and type of securities to be quoted, issue dates, and the resulting issued capital. There is no financial performance data, management discussion, or report content. The document is a formal announcement related to capital changes, specifically the issuance and quotation of new shares due to option exercises. This fits the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains detailed information about the securities issued, not just a brief announcement or a report publication notice.
2022-08-16 English
Notification of cessation of securities - OCC 5 pages 25.3KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry and cessation of certain options (unquoted equity securities) for Orthocell Limited. It includes specific information about the securities that have ceased, the reasons for cessation (expiry of options), and the updated issued capital following these changes. The document is a formal announcement about changes in the company's issued securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor an earnings release or audit report. It is also not a regulatory filing in the sense of officer certifications or legal proceedings. The content fits best with announcements related to changes in capital structure or securities issued by the company. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 4213 characters, which is consistent with a detailed announcement rather than a full report.
2022-08-16 English
Notice under Section 708(A) of the Corporations Act 2 pages 152.1KB
Regulatory Filings Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, compliance statements, and contact information. The document is short (3242 characters) and serves as a regulatory announcement about a share issue rather than a full financial report or detailed capital update. It does not contain financial statements or substantive financial data, nor is it a report or presentation. This type of notice is best classified as a Regulatory Filing (RNS) because it is a formal compliance announcement that does not fit other specific categories like Capital/Financing Update or Share Issue/Capital Change, which typically involve more detailed disclosures or financial data. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2022-08-16 English
Appendix 4C - Quarterly 8 pages 555.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report – June 2022' and is dated 29 July 2022. It provides detailed financial and operational highlights for the quarter ended 30 June 2022, including cash inflows, licensing agreements, clinical trial updates, regulatory approvals, and commercial activities. The content includes substantive financial data such as cash balances, revenue from licensing agreements, and R&D tax incentives, as well as detailed business updates and clinical trial progress. The length of the document (15,000 characters) and the depth of information indicate it is a comprehensive report rather than a brief announcement or presentation. The document fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the appropriate classification is IR with high confidence. Q4 2022
2022-07-28 English
Updated Investor Presentation 27 pages 6.4MB
Investor Presentation Classification · 95% confidence The document is titled 'Updated Investor Presentation' and is described as an investor presentation used for a healthcare conference and investor meetings. It contains detailed information about the company's products, market opportunities, strategic partnerships, financial snapshot, and forward-looking statements. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The content is consistent with a presentation aimed at investors to provide an update on company strategy, product pipeline, and market positioning. Therefore, the document fits the category of an Investor Presentation (IP). The document length is substantial (15,000 characters), and it contains detailed content rather than just an announcement or a brief summary, supporting this classification with high confidence.
2022-07-26 English
Striate Global License and Distribution Agreement Update 2 pages 218.3KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a global exclusive license and distribution agreement between Orthocell Limited and BioHorizons Implant Systems Inc. It details the terms of the agreement, the payment received, and background information about the companies and products involved. There are no financial statements, quarterly or annual results, or detailed financial performance data. The document is not a report but an update on a capital transaction (license and distribution agreement) involving a significant cash inflow. This fits the category of Capital/Financing Update (CAP). The document length is 6826 characters, which is sufficient for a substantive announcement rather than a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2022-07-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.